Children, Adolescents and Young Adults with Myeloproliferative Neoplasia: Study of Clinico-biological Characteristics and Complications

University Hospital, Brest1 site in 1 country200 target enrollmentApril 1, 2023

ConditionsMyeloproliferative Neoplasm

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Myeloproliferative Neoplasm
Sponsor: University Hospital, Brest
Enrollment: 200
Locations: 1
Primary Endpoint: Describe the epidemiological characteristics of the study population
Status: Recruiting
Last Updated: last year

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The creation of a national database will provide access to solid data on the diagnosis of myeloproliferative neoplasia for patients under 30, giving a true picture of their care. It will also make it possible to identify the biological samples (histological and molecular) available in routine laboratories, enabling teams of researchers and anatomopathologists to (re)perform certain analyses to re-evaluate diagnoses and search for hitherto unknown molecular prognostic factors.

Registry

clinicaltrials.gov

Start Date

April 1, 2023

End Date

April 1, 2038

Last Updated

last year

Study Type

Observational

Sex

All

Investigators

Sponsor

University Hospital, Brest

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Patient diagnosed with non-LMC MPN before the age of 30 (PV or TE or MFP or PreMF) according to the 2016 WHO criteria.
•Signature of the consent form for participation in the FIMBANK project.
•Agreement to participate in the VYP study.
•Patient of legal age at the time of inclusion in VYP.
•Patient affiliated to a social security scheme

Exclusion Criteria

•Refusal to participate by patients of full age
•Patient under legal protection (guardianship, curatorship, etc.)

Outcomes

Primary Outcomes

Describe the epidemiological characteristics of the study population

Time Frame: at enrollment

Description of MPN subtypes according to age

Describe the mutational landscape of these MPNs

Time Frame: at enrollment

Rate of mutations JAK2/CALR/MPL

Secondary Outcomes

Describe the classical MPN (Myeloproliferative neoplasia) outcomes-1(At 10 years)
Describe the classical MPN outcomes-2(At 10 years)
Describe the classical MPN outcomes-3(At 10 years)